Q120 remained a bright spot showing positive growth with modest disruption from COVID-19 for the quarter.

For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, the US Infection Prevention - Vascular Access Adjunct Products market was up +4. 4% YoY. The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Among the many topics covered in the comprehensive Q120 Infection Prevention: Vascular Access Adjunct Products Recap Market Recap* are:

In Q120, the US and EU AWC markets experienced modest gains, offset by ROW (China) hit early in the quarter with COVID-19.

For Q120, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +2.2% YoY. Many companies commented on the impact of COVID-19 on their business performance. Overall, the impact in Q120 was limited, as the pandemic hit in March in most countries, whereas Jan and Feb were more business as usual. All are expecting a more severe impact in Q220, and almost all companies have withdrawn their FY20 projections.

Among the many topics covered in the comprehensive Q120 Advanced Wound Care Market Recap* are:

.SmartTRAK discusses a new biomaterials opportunity for medical devices with Michael Ziebell, President and CEO of trū Shrimp.

Shrimp is the most popular seafood in the US with an annual consumption of 1.6 billion pounds and 90% sourced outside the US. trū Shimp has developed a unique aquaculture for raising shrimp that allows production to occur anywhere in the US, even in Minnesota. Michael Ziebell explains the unique features of the process and its ability to produce a novel biomaterial that may be tailored to meet the needs of the medical device industry.

A transcript of SmartTRAK’s interview with Michael Ziebell is below. To listen to the audio interview, click on the video (10:39 minutes). The full transcript, with a link to download a PDF, is provided below.

FY19 showed solid gains in all segments, up +4.1% YoY, as antimicrobial devices take the lead

The prevention of Hospital-Acquired Infections (HAIs) continues to drive measures and practices to reduce Central Line-Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. Numerous programs and educational tools are being developed to provide measures and strategies that assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

According to BioMedGPS' SmartTRAK Financial Dashboard, the Q419 US VA Adjunct Products market saw a solid increase of +3.7% for the four segments: Dressings, Antimicrobial Devices, Antimicrobial IV Skin Preps and Mechanical Securement Devices.

Among the many topics including news, financial data, charts and company revenues, covered in the comprehensive Q419/FY19 Infection Prevention: Vascular Access Adjunct Products Market Recap*, are:

A year of solid growth and acquisitions for the WW AWC market, as 3M moves into the leading position.

For FY19, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +4.7% YoY.

3M captured the number one position in the AWC space after completing the acquisition of Acelity and its KCI subsidiaries on October 11, 2019. According to SmartTRAK Financial Dashboard, in FY19, combined 3M and Acelity seized 22.7% of the market and generated +6.2% YoY growth. Revenue for Q419 was up +6.9% YoY, driven by ongoing strong performance in single-use negative pressure wound therapy and solid growth in Advanced Wound Dressings. 

Among the many topics, including news, financial data, charts and company revenues, covered in the comprehensive Q419/FY19 Advanced Wound Care Market Recap*,  are:

Marcia Nusgart, Executive Director, Alliance of Wound Care Stakeholders, discusses the upcoming Wound Care Evidence Summit and improving payer coverage in an interview with SmartTRAK.

In the market for wound care products, the success of any product is highly dependent on whether or not manufacturers are able to obtain a positive coverage determination from public and commercial payers. In the last several years, obtaining product reimbursement has been more challenging as payers are restricting coverage for a growing number of wound care products due to a lack of clarity surrounding clinical evidence.

So, what are payers looking for? What and how much clinical evidence do payers need to cover wound care products and procedures? How can manufacturers prepare scientific evidence to meet payer needs, improve coverage and achieve more uniform policies for treating wounds in all healthcare settings? To answer these questions and more, the Alliance of Wound Care Stakeholders is convening payers, regulators, researchers, manufacturers and wound care providers at its upcoming Wound Care Evidence Summit to be held April 1-2, 2020 in Washington, DC.

To find out about the Summit, improving payer coverage and opportunities for industry, SmartTRAK’s Susan Paquette interviewed Marcia Nusgart, Executive Director of the Alliance of Wound Care Stakeholders.

Positive gains in the mid-single digits for Q319, a slight decrease from previous quarter

Prevention of HAIs continues to drive measures and practices to reduce Central Line Associated Bloodstream Infections (CLABSIs) and is creating demand for products that can address these issues. In response, numerous programs and educational tools are being launched providing measures and strategies to assist healthcare providers in the prevention and reduction of infection in acute care and other settings.

Last quarter, a coalition of nurses and the AVA launched a drive to support a safety initiative for placing vascular access specialists in every hospital across America. This theme continued at this year’s AVA conference with the mission statement of “Protect the Patient, Educate the Clinician and Save the Line” highlighting the overall focus for the event. Acknowledgment of the importance of the vascular access nurse and team were featured in numerous studies and presentations demonstrating the value of the vascular access team in practice...

Among the many topics covered in the complete, comprehensive Q319 US Infection Prevention Market Recap* are:

Another quarter of strong growth, but slower growth clouds building up on the horizon here and there. Both Smith+Nephew and ConvaTec have newly appointed CEOs.

For Q319, according to SmartTRAK’s Financial Dashboard, WW Advanced Wound Care (AWC) revenue for Advanced Dressings, External Devices and Biologics was up +5.9% YoY.

Acelity remained the WW AWC market leader, up +6.3% YoY, driven by  Prevena and the Crawford acquisition. WW Advanced Dressings saw several strong shifts in the ranking of companies, with ConvaTec moving up to the 2nd position, surpassing Smith + Nephew (S+N), after ConvaTec recovering, but S+N facing continued declining growth. Mölnlycke led the market and Coloplast was the strongest growing of the top four. The total market was up +3.2% YoY. US Skin/Dermal Substitute (CTP) revenue increased, with xenografts, especially  Organogenesis’  PuraPly, driving gains. WW NPWT was up  +8.2% YoY, with traditional devices up +3.4% and single-use...

Among the many topics covered in the complete, comprehensive Q319 Advanced Wound Care Market Recap* are:

AVA Scientific Meeting 2019 highlights key opportunities for improvement in vascular access from process bundles to emerging new products

Introduction

Acknowledgment of the importance of the vascular access nurse and team were obvious at this year’s Association for Vascular Access (AVA) Annual Scientific meeting. When Ramzy Nasrallah took over as CEO for the Association of Vascular Access (AVA) in 2017, he consolidated the mission of AVA “Protect the Patient, Educate the Clinician and Save the Line” to make it more memorable and to create a more powerful message. (See SmartTRAK interview with Nasrallah at AVA 2017). Nasrallah’s ultimate goal for AVA is to be “the biggest, most reputable, and highly regarded healthcare association in the world” with tens of thousands of members globally. Since taking the helm and advancing his agenda...

Dr. Ronald Baxter of Baylor University and Spectral MD, discusses the Spectral MD DeepView Wound Imaging System in predicting DFU wound healing utilizing artificial intelligence in an interview with SmartTRAK.

Spectral MD has developed the DeepView Wound Imaging System to utilize real-time data and artificial intelligence to predict wound healing. The Company has seen initial success in burn treatment and is now moving into validation of their system for diabetic foot ulcers with the goal to predict a wound’s healing potential at the initial clinical visit.

To learn more about Spectral MD’s multi-spectral imaging system, DeepView; the pilot DFU study to analyze the predictive qualities of its artificial intelligence deep learning program, and the company’s plans moving forward, SmartTRAK interviewed Dr. Ronald Baxter, of Baylor University and Spectral MD.

To view the interview, recorded live at SAWC Spring 2019, click on the following video. A transcript of SmartTRAK’s interview with Dr. Baxter is below.